When and How Often PSMA-PET Imaging Should be Used

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

We preview several noteworthy P2 presentations in the urologic oncology space.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.